[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2009066562A1 - Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine - Google Patents

Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine Download PDF

Info

Publication number
WO2009066562A1
WO2009066562A1 PCT/JP2008/070042 JP2008070042W WO2009066562A1 WO 2009066562 A1 WO2009066562 A1 WO 2009066562A1 JP 2008070042 W JP2008070042 W JP 2008070042W WO 2009066562 A1 WO2009066562 A1 WO 2009066562A1
Authority
WO
WIPO (PCT)
Prior art keywords
methionine
anemia
thr
preventing
promoter
Prior art date
Application number
PCT/JP2008/070042
Other languages
French (fr)
Japanese (ja)
Inventor
Yukio Asami
Original Assignee
Meiji Dairies Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiji Dairies Corporation filed Critical Meiji Dairies Corporation
Priority to JP2009542517A priority Critical patent/JPWO2009066562A1/en
Priority to CN200880117597A priority patent/CN101868230A/en
Publication of WO2009066562A1 publication Critical patent/WO2009066562A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

It is a first object to develop a remedy efficacious in preventing senile anemia which is frequently observed due to the aging. It is a second object to provide an antiaging drug, which has little side effect and is inexpensive and efficacious, in anticipation of the coming aging society. It is a third object to provide a remedy which is efficacious against anemia caused by myelosuppression, more particularly speaking, anemia occurring as the side effect of the administration of an anticancer agent. It has been clarified for the first time that a drug containing, as the active ingredient, methionine (Met) alone, an amino acid composition containing methionine (Met) together with one or more members selected from among glycine (Gly), serine (Ser) and threonine (Thr) or, furthermore, an amino acid mixture selected from (1) Ile, Trp, Thr, Val, His, Phe,Lys and Leu, (2) Ile, Thr, Val, His, Lys and Leu, (3) Trp, Thr, His, Phe and Lys, and (4) Ile, Trp, Thr, Val, Phe and Leu is capable of ameliorating and healing senile anemia. Thus, preventives for senile anemia, remedies for senile anemia and drugs for preventing cell aging can be provided.
PCT/JP2008/070042 2007-11-20 2008-11-04 Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine WO2009066562A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2009542517A JPWO2009066562A1 (en) 2007-11-20 2008-11-04 Erythrocyte stem cell differentiation promoter and / or proliferation promoter, and use of methionine for preventing or treating senile anemia and a composition containing methionine
CN200880117597A CN101868230A (en) 2007-11-20 2008-11-04 Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007300814 2007-11-20
JP2007-300814 2007-11-20

Publications (1)

Publication Number Publication Date
WO2009066562A1 true WO2009066562A1 (en) 2009-05-28

Family

ID=40667387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/070042 WO2009066562A1 (en) 2007-11-20 2008-11-04 Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine

Country Status (4)

Country Link
JP (1) JPWO2009066562A1 (en)
KR (1) KR20100098400A (en)
CN (1) CN101868230A (en)
WO (1) WO2009066562A1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012147901A1 (en) * 2011-04-28 2012-11-01 味の素株式会社 Composition for mitigating anticancer drug side effects
JP2018050551A (en) * 2016-09-29 2018-04-05 日本メナード化粧品株式会社 Agent for promoting differentiation of hematopoietic stem cell
WO2022250040A1 (en) * 2021-05-25 2022-12-01 味の素株式会社 Composition for improving or preventing iron deficiency anaemia

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510145A (en) * 1997-07-14 2001-07-31 エヌ・ヴイ・ヌートリシア Nutritional composition containing methionine
JP2003155234A (en) * 2001-11-20 2003-05-27 Fancl Corp Antiaging composition
JP2004519241A (en) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Composition that improves physiological disorders associated with aging and extends lifespan
JP2005198642A (en) * 2003-12-15 2005-07-28 Yutaka Miyauchi Liquid drinking product using fruit skin of citrus fruit as raw material
WO2007029730A1 (en) * 2005-09-06 2007-03-15 Meiji Dairies Corporation Amino acid composition for prevention or treatment of senile anemia

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001510145A (en) * 1997-07-14 2001-07-31 エヌ・ヴイ・ヌートリシア Nutritional composition containing methionine
JP2004519241A (en) * 2001-03-09 2004-07-02 ソシエテ デ プロデユイ ネツスル ソシエテ アノニム Composition that improves physiological disorders associated with aging and extends lifespan
JP2003155234A (en) * 2001-11-20 2003-05-27 Fancl Corp Antiaging composition
JP2005198642A (en) * 2003-12-15 2005-07-28 Yutaka Miyauchi Liquid drinking product using fruit skin of citrus fruit as raw material
WO2007029730A1 (en) * 2005-09-06 2007-03-15 Meiji Dairies Corporation Amino acid composition for prevention or treatment of senile anemia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KARASAWA, M. ET AL.: "Methionine Partially Corrects the Impaired Deoxyribonucleic Acid Synthesis of B12-deficient Megaloblastic BBone Marrow Cells at Low Concentration", JAP. J. MED., vol. 25, no. 2, 1986, pages 155 - 161 *
MASSOBRIO, V. et al, The antianemic action of methionine, Chemical Abstracts, 1952, Vol.47, 3976 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012147901A1 (en) * 2011-04-28 2012-11-01 味の素株式会社 Composition for mitigating anticancer drug side effects
JP2018050551A (en) * 2016-09-29 2018-04-05 日本メナード化粧品株式会社 Agent for promoting differentiation of hematopoietic stem cell
WO2022250040A1 (en) * 2021-05-25 2022-12-01 味の素株式会社 Composition for improving or preventing iron deficiency anaemia

Also Published As

Publication number Publication date
JPWO2009066562A1 (en) 2011-04-07
KR20100098400A (en) 2010-09-06
CN101868230A (en) 2010-10-20

Similar Documents

Publication Publication Date Title
Magne et al. Nutritional strategies to counteract muscle atrophy caused by disuse and to improve recovery
US20160136231A1 (en) Topical formulations of chemerin c15 peptides for the treatment of dermatological conditions
GEP20125628B (en) Pharmaceutical compositions containing antagonist anti-cd40 antibody
Rastaldo et al. Effect of apelin-apelin receptor system in postischaemic myocardial protection: a pharmacological postconditioning tool?
UA90521C2 (en) Pharmaceutical composition comprising simvastatin and ezetimibe
WO2008124505A3 (en) Soluble guanylate cyclase (sgc) modulators for treatment of lipid related disorders
TW200733968A (en) Stabilized lanthanum carbonate compositions
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
WO2006017251A3 (en) Compositions for delivering peptide yy and pyy agonists
WO2010030180A3 (en) Peptide formulations and uses thereof
WO2007061829A3 (en) Pharmaceutical composition
WO2011019617A3 (en) Vitamin d3 and analogs thereof for treating alopecia
BRPI0508579A (en) compound, pharmaceutical composition, and use of a compound
WO2009066562A1 (en) Differentiation promoter and/or proliferation promoter for erythrocyte stem cells, use of methionine for preventing or treating senile anemia, and compositions containing methionine
WO2008014256A3 (en) Composition including superoxide dismutase and prickly-pear cactus for minimizing and preventing hangovers
WO2010041832A3 (en) Antioxidant active composition containing an ishige okamurae-derived compound
MX2010004556A (en) Pharmaceutical formulation of clavulanic acid.
WO2006050002A3 (en) Compositions for controlled delivery of pharmaceutically active compounds
WO2007042010A3 (en) Synergistic pharmaceutical composition containing a peptide with 2 to 5 amino acids
WO2008063563B1 (en) Methods of treating keratin hyperproliferation disorders using mtor inhibitors
WO2020141828A3 (en) Anticancer compositions comprising immune checkpoint inhibitors
CA2704100C (en) Compositions and methods for treating fibroproliferative disorders
BRPI0418743A (en) methods of treating, preventing or controlling a myelodysplastic syndrome, reducing or preventing an adverse effect associated with the administration of a second active ingredient in a patient suffering from a myelodysplastic syndrome, pharmaceutical composition, single unit dosage form, and kit
WO2007135268A3 (en) Use of peptides as active slimming ingredients
WO2007027092A3 (en) Oral composition for moisturising skin

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880117597.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08852192

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2009542517

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 20107013462

Country of ref document: KR

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 08852192

Country of ref document: EP

Kind code of ref document: A1